



**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

- ☐ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.
- ☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.
- ☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.
- ☒ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.
- ☒ The fee due under 37 CFR § 1.17(p) is submitted herewith.
- ☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
- ☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

- ☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- ☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- ☒ A check in the amount of \$180.00 is enclosed for the above fee(s).
- ☐ Please charge \_\_\_\_\_ to Deposit Account No. **12-2475** for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
LYON & LYON LLP

Dated: 4/16/01

By: Charles M. Doyle  
Charles M. Doyle  
Reg. No. 39,175



22249


LYON & LYON LLP  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071  
(914) 681-8851

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.


Applicant: McDonald, G., et al.  
Serial No.: 09/753,814  
For: METHOD OF LONG-TERM TREATMENT OF GRAFT-VERSUS-HOST  
DISEASE USING TOPICAL ACTIVE CORTICOSTEROIDS  
Filed: January 3, 2001

**TRANSMITTAL**

Attorney(s): Charles M. Doyle, Esq.  
Docket No.: 259/284  
Date of Deposit: April 16, 2002  
Enclosure(s): Transmittal Form with Certificate of Mailing; Information Disclosure Statement;  
PTO Form 1449 with copies of Prior Art References; Fee Transmittal Form;  
Lyon & Lyon check no. 15605 in the amount of \$180.00; Return Postcard.



Charles M. Doyle, Esq.  
Lyon & Lyon, LLP  
633 West Fifth Street, Suite 4700  
Los Angeles, California 90071-2066



LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:

McDonald, George B. and Nicholas Stergiopoulos

FILING DATE:

January 3, 2001

GROUP:

1617

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA	5,403,833	04/04/95	Calme	514	171	
	AB						
	AC						
	AD						
	AE						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	AI						
	AJ						
	AK						

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	AL	Storb, R. And Thomas, D., "Graft-versus-Host Disease in Dog and Man: The Seattle Experience", 1985, <i>Immunological Rev.</i> 88:216-238.
	AM	Storb, R. et al., "What Role for Prednisone in Prevention of Acute Graft-versus-Host Disease in Patients Undergoing Marrow Transplants?", 1990, <i>Blood</i> 76(5):1037-1045.
	AN	Sayer, H.G. et al., "Increased Risk of Infection in Marrow Transplant Patients Receiving Methylprednisolone for Graft-versus-Host Disease Prevention", 1994, <i>Blood</i> 84(4):1328-1332.
	AO	Deeg, H.J. et al., "Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial",
	AP	Nash, R.A. and Storb, R., "Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL", 1996, <i>Curr. Op. Immunol.</i> 8(5):674-680.
	AQ	Chao, N.J., "Pharmacology and Use of Immunosuppressive Agents After Hematopoietic Cell Transplantation", in <i>Hematopoietic Cell Transplantation</i> , Thomas, E.D. et al. (eds.), 2 <sup>nd</sup> Ed. pp. 176-185. Blackwell Scientific Publications, Boston, MA.
	AR	Singh, C. and McDonald, G.B., "Intestinal and Hepatic Complications of Bone Marrow and Stem Cell Transplantation", in <i>Gastrointestinal Emergencies</i> , Taylor, M.B. et al., eds., Williams & Wilkins, Baltimore (1997).
	AS	Kernan, N.A., "T-Cell Depletion for the Prevention of Graft-Versus-Host Disease", in <i>Hematopoietic Cell Transplantation</i> , Thomas, E.D. et al. (eds.), 2 <sup>nd</sup> Ed. pp. 186-196. Blackwell Scientific Publications, Boston, MA.
	AT	Ferrara, J.L.M. and Antin, J. H., "The Pathophysiology of Graft-Versus-Host Disease", in <i>Hematopoietic Cell Transplantation</i> , Thomas, E.D. et al. (eds.), 2 <sup>nd</sup> Ed. pp. 305-315. Blackwell Scientific Publications, Boston, MA.

EXAMINER:

Jiang, S.

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant